Etoposide for epidemic Kaposi's sarcoma: a phase II study.
Fourteen untreated patients with epidemic Kaposi's sarcoma stages III and IV were treated with etoposide 150 mg/m2 on 3 consecutive days every 4 weeks. No responses were observed. Myelosuppression was severe with white blood count WHO grade 3-4 in nine patients and with platelets WHO grade 3-4 in one patient. Three patients developed opportunistic infections during therapy. It is concluded that etoposide is inactive in epidemic Kaposi's sarcoma.